Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Determine the SP 500 fund with the best 15-year return and understand factors driving the outperformance over this horizon.
28,427 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Anthropic is widening who can tap into Claude Mythos, just as IPO chatter heats up in the AI arena. This move could r...
San Francisco rolls out the Year of the Fire Horse parade with Olympic champion Eileen Gu as grand marshal, spotlight...
A closer look at dividend aristocrats with multi-decade payout streaks and what their steady income track means for i...
Planning for downturns is not optional—it's essential. This guide shows you how to recession-proof your retirement be...
With $850,000 saved at 59, a couple can expect about $2,600-$2,800 a month in early retirement from portfolios, befor...
New data on the gender wage gap show women still earn far less than men, marking a second straight year of ground los...
As IPOs continue to attract capital, one recent entrant stands out. This article breaks down why wall street expects ...
A veteran software developer weighs early retirement as AI reshapes the field. With a paid-off home and a sizable por...
As KVHI gears up for the 2025 earnings call, investors should focus on revenue drivers, margins, and long-term strate...
Andersen Group surged on surprise Q4 strength and an optimistic outlook. This deep dive explains what drove the rally...
A retiree keeping 90% of a $1.7M portfolio in cash faces about $39,000 a year in lost growth, underscoring the long-t...